Ependymoma
MONDO:0016698A WHO grade II, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)
Also known as: benign ependymoma, ependymoma, WHO grade II ependymal neoplasm, WHO grade II ependymal tumor, WHO grade II ependymal tumour, ependymoma, benign, clear cell ependymoma (histologic variant), ependymoma, familial
1535 clinical trials for this condition and its sub-types, 87 tagged with Ependymoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Ependymoma
-
Childhood ependymoma 7 trials
1 sub-type
- Pediatric supratentorial ependymoma 0 trials
-
Cellular ependymoma 1 trial
-
Clear cell ependymoma 1 trial
-
Papillary ependymoma 1 trial
-
Low grade ependymoma 0 trials · 1 incl. sub-types
1 sub-type
- Subependymoma 1 trial Sub-types →
-
Brain stem ependymoma 0 trials
-
Spinal cord ependymoma 0 trials
2 sub-types
- Adult spinal cord ependymoma 0 trials
- Spinal ependymoma, MYCN-amplified 0 trials
-
Tanycytic ependymoma 0 trials
Most studied deeper sub-types
-
New combo therapy shows promise for kids with tough cancers
Disease control Stopped earlyThis study tested a combination of an immunotherapy drug (nivolumab) and low-dose chemotherapy in children and teenagers whose solid tumors had not responded to standard treatments. The goal was to see if the combination was safe and could help control the cancer. The trial was s…
Phase 1/2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can an immune booster fight rare brain tumors?
Disease control Stopped earlyThis phase 2 trial tests whether the immunotherapy drug nivolumab can shrink tumors or slow their growth in adults with rare central nervous system (brain or spine) tumors that have returned after prior treatment. Participants receive nivolumab by IV every 2 to 4 weeks for up to …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New immunotherapy attempts to fight childhood brain cancer
Disease control Stopped earlyThis early-stage study tested a new immunotherapy approach for children whose ependymoma (a type of brain tumor) had come back after standard treatment. The therapy combined a peptide vaccine designed to train the immune system to attack tumor cells with a skin cream (imiquimod) …
Phase 1 • Sponsor: James Felker • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Spinal tap could replace brain surgery for young tumor patients
Knowledge-focused Stopped earlyThis study looked at whether a liquid biopsy—testing the fluid around the brain and spinal cord—can find tumor DNA in children and young adults with brain tumors. The goal was to see if this safer, non-surgical test could replace risky tissue biopsies for diagnosis and monitoring…
Sponsor: Pediatric Brain Tumor Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists examine stored tumor samples to uncover DNA clues in Kids' brain cancers
Knowledge-focused Stopped earlyThis study looked at stored tumor samples from 139 children with brain and central nervous system tumors. Researchers wanted to find DNA changes and biomarkers that could help understand these cancers better. The study was terminated early, so results may be limited.
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC